Kenney Paula M, Bennett James P
Neurodegeneration Therapeutics, Inc., Charlottesville, VA, USA.
Int J Alzheimers Dis. 2019 Mar 5;2019:4814783. doi: 10.1155/2019/4814783. eCollection 2019.
Alzheimer's disease (AD), the most common cause of sporadic dementia of in adults, shows increased risk of occurrence with aging and is destined to become a major sociomedical tragedy over the next few decades. Although likely complex in origin, sporadic AD is characterized by a progressive and stereotyped neuropathology with aggregated protein deposition (esp beta amyloid (BA) and hyperphosphorylated tau (P-tau)) and neuronal degeneration. To date, prevention of BA synthesis or immune-mediated removal of BA has failed to alter AD progression. Development and testing of P-tau therapeutics are a work in progress. AD brain tissues show multiple system deficits, including loss of respiratory capacity. In the present study there were no differences in mitochondrial mass between AD and CTL samples. We examined mitochondrial preparations of postmortem AD and CTL frontal cortex for relative levels of individual respiratory protein complexes by Western immunoblotting. ANOVA revealed deficiencies of all respiratory complex subunits in AD; post-ANOVA t-testing revealed significant differences in levels of subunits for complexes II, III, and V, borderline significance for subunit of complex IV, and no difference for subunit of complex I. We also examined mitochondrial extracts with blue-native gel electrophoresis combined with immunoblotting for subunits of complexes I and III to search for "respiratory supercomplexes" (RSC's). We found that levels of RSC's did not differ between AD and CTL samples. Mitochondrial preparations from end-stage AD brain tissue showed loss of individual ATP-producing respiration subunits but preservation of levels of assembled respiratory subunits into RSC's. Possible explanations include insufficient sensitivity of our method of RSC detection to find loss of individual subunits, or normal levels of RSC's in AD brain mitochondria coupled with decreased levels of nonassembled respiratory complex subunits. Disease-altering therapies of early AD could include stimulation of mitochondrial biogenesis to overcome loss of respiratory subunits.
阿尔茨海默病(AD)是成人散发性痴呆最常见的病因,其发病风险随年龄增长而增加,在未来几十年注定会成为一场重大的社会医学悲剧。尽管其病因可能很复杂,但散发性AD的特征是具有进行性和刻板性的神经病理学改变,伴有蛋白质聚集沉积(尤其是β淀粉样蛋白(BA)和过度磷酸化的tau蛋白(P-tau))以及神经元变性。迄今为止,预防BA合成或通过免疫介导清除BA均未能改变AD的进展。P-tau治疗方法的研发和测试正在进行中。AD脑组织显示出多种系统缺陷,包括呼吸功能丧失。在本研究中,AD样本和对照(CTL)样本之间的线粒体质量没有差异。我们通过蛋白质免疫印迹法检测了死后AD和CTL额叶皮质的线粒体提取物中各个呼吸蛋白复合物的相对水平。方差分析显示AD中所有呼吸复合物亚基均有缺陷;方差分析后的t检验显示复合物II、III和V的亚基水平存在显著差异,复合物IV的亚基水平接近显著差异,复合物I的亚基水平无差异。我们还通过蓝色非变性凝胶电泳结合免疫印迹法检测线粒体提取物中复合物I和III的亚基,以寻找“呼吸超级复合物”(RSC)。我们发现AD样本和CTL样本之间RSC的水平没有差异。晚期AD脑组织的线粒体提取物显示单个产生ATP的呼吸亚基缺失,但组装成RSC的呼吸亚基水平保持不变。可能的解释包括我们检测RSC的方法灵敏度不足,无法发现单个亚基的缺失,或者AD脑线粒体中RSC水平正常,但未组装的呼吸复合物亚基水平降低。早期AD的疾病改善疗法可能包括刺激线粒体生物合成以克服呼吸亚基的缺失。